Boxer Capital’s $18 Million Corvus Pharma Bet Signals Confidence in This Biotech’s Next Phase Corvus Pharmaceuticals develops immuno-oncology therapies, advancing clinical candidates for cancer and immune-related conditions.
Why One Healthcare Fund Increased Its Kodiak Sciences Stake Amid an Eye-Popping Rally This clinical-stage biotech develops innovative retinal disease therapies, with its lead candidate advancing through late-stage trials.
Vir Biotechnology Stock Has Doubled This Past Year. One Fund Just Bought 1.2 Million Shares Vir Biotechnology develops antibody and RNA-based therapies for infectious diseases, leveraging partnerships and a robust clinical pipeline.
Acuta Capital Bet on Erasca (ERAS) and Targeted Cancer Treatments With a 354,575 Share Buy This San Diego biotech develops targeted therapies for RAS/MAPK-driven cancers, advancing several clinical candidates in oncology.
Tango Therapeutics President Sells 27,000 Shares for $572,000 as Share Price Skyrockets This precision oncology developer reported a notable insider sale during a period of robust share price gains.
Tango Therapeutics Insider Sells $304,000 in Stock Amid a 36% Single-Day Surge This clinical-stage biotech focused on targeted cancer therapies reported a notable insider sale.
Is Relay Therapeutics a Buy in 2026? One Institutional Investor Just Made a $6 Million Bet. Relay Therapeutics develops precision oncology medicines using proprietary computational modeling and strategic industry partnerships.
Nextech Trims Kymera at a Recent High — think Foolishly before acting. Kymera Therapeutics develops targeted protein degradation therapies for immunology and oncology, advancing a diversified clinical pipeline.
Investment Firm Doubles Down on Biotech Stock, Adds 386,000 Shares, According to Recent SEC Filing This clinical-stage biotech targets retinal diseases with late-stage drug candidates and a focused pipeline in ophthalmology.
Investment Manager Loads Up on CELC Stock, Adds 135,000 Shares, According to Latest SEC Filing This clinical-stage biotech develops precision oncology therapies and diagnostics targeting unmet needs in breast and ovarian cancer.
Investment Firm Builds Position in TERN Stock, According to Recent SEC Filing This clinical-stage biotech develops small-molecule therapies for liver and metabolic diseases, targeting unmet needs in NASH and obesity.
Investment Firm Bets Big on TNGX Stock With $9.5 Million Purchase, According to Recent SEC Filing This clinical-stage biotech develops targeted cancer therapies, leveraging strategic partnerships and a differentiated oncology pipeline.
The $20 Billion Question: Revolution Medicines Surges as Big Pharma Circles the Pan-RAS Leader The first week of 2026 has set the biotech sector ablaze, with Revolution Medicines (
NASDAQ: RVMD ) finding itself at the epicenter of a high-stakes acquisition tug-of-war. Shares of the Redwood City-based oncology specialist experienced a roller-coaster session following reports that Big Pharma titan AbbVie (
NYSE: ABBV ) was in advanced discussions
TANGO THERAPEUTICS INC (NASDAQ:TNGX) Posts Strong Q3 Earnings Beat Amid Mixed Market Reaction Tango Therapeutics (TNGX) reported a strong Q3, beating revenue and EPS estimates. Despite the earnings beat, the stock saw mixed market reaction.
Tango Therapeutics Touts Encouraging Data From Early-Stage Cancer Trial, Raises Capital To Fund Advancement Tango Therapeutics Inc. (
NASDAQ:TNGX ) revealed data from its ongoing Phase 1/2 study of vopimetostat (TNG462) in patients with MTAP-deleted cancers.
Wondering what's happening in today's pre-market session? Discover the top movers in Thursday's pre-market session and stay informed about market dynamics.
Tango Therapeutics Stock Soars Pre-Market On $225M Financing, Positive Study Data For Cancer Therapy CEO Barbara Weber said that across the 16 cancer types enrolled in the trial, the objective response rate (ORR) was 27% in patients with a median follow-up of 9.4 months.
Tango Therapeutics Inc (NASDAQ:TNGX) Reports Q2 2025 Earnings: Revenue Misses, EPS Meets Expectations Amid Clinical Progress Tango Therapeutics (TNGX) reported Q2 2025 revenue below estimates but met EPS expectations, causing a 2.4% pre-market dip. Clinical progress in oncology trials remains a key focus.
